EGFR tyrosine kinase inhibitor
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:category |
targeted therapy
|
| gptkbp:contraindication |
hypersensitivity to drug
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:drugInteraction |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:example |
gptkb:afatinib
gptkb:erlotinib gptkb:gefitinib gptkb:osimertinib |
| https://www.w3.org/2000/01/rdf-schema#label |
EGFR tyrosine kinase inhibitor
|
| gptkbp:mechanismOfAction |
inhibits EGFR tyrosine kinase activity
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
rash interstitial lung disease |
| gptkbp:target |
gptkb:epidermal_growth_factor_receptor
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
metastatic lung cancer EGFR-mutant cancers |
| gptkbp:bfsParent |
gptkb:Tagrisso
gptkb:162359-55-9 |
| gptkbp:bfsLayer |
6
|